Innovation, product type and industrial protection – the keys to the success of Spain's Farma-Biotech's program

10 October 2016

Small biotech companies and start-ups, R&D centers and pharmaceutical companies in Spain have highlighted the benefits that the Farma-Biotech program has generated for their activities.

The Program was set up five years ago by the Spanish trade group Farmaindustria, and a summary of its recent activities was presented last week in Bilbao in the context of the Biospain fair.

The initiative, which fosters the cooperation of the pharmaceutical industry with small biotechnology companies, universities, hospitals and R&D centers, largely bases its success on its projects selection criteria: therapeutic area of innovation, product type, innovative action mechanism, degree of differentiation to other developments or products, phase of advance in the development of medicine and status of industrial protection.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK